A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Crossover Study to Evaluate the Efficacy and Safety of Lorundrostat in Participants With Moderate to Severe Obstructive Sleep Apnea and Hypertension
Latest Information Update: 25 Jan 2025
Price :
$35 *
At a glance
- Drugs Lorundrostat (Primary)
- Indications Hypertension; Sleep apnoea syndrome
- Focus Therapeutic Use
- Sponsors Mineralys Therapeutics
- 16 Jan 2025 Status changed from planning to not yet recruiting.
- 13 Jan 2025 New trial record
- 08 Jan 2025 According to Mineralys Therapeutics media release, Initiation of the trial anticipated in the first quarter of 2025.